Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Intangibles (2024 - 2025)

Myriad Genetics (MYGN) has disclosed Change in Intangibles for 2 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Intangibles fell 43.48% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.8 million, a 10.28% increase, with the full-year FY2025 number at $11.8 million, up 10.28% from a year prior.
  • Change in Intangibles was $1.3 million for Q4 2025 at Myriad Genetics, down from $3.4 million in the prior quarter.
  • In the past five years, Change in Intangibles ranged from a high of $4.1 million in Q2 2025 to a low of $1.3 million in Q4 2025.